Arca
Skip to content
Tools
Tools

KMT2A, MEN1: Menin/Histone-lysine N-methyltransferase MLL

Interaction in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on KMT2A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Revumenib

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        RevumenibBoxed warningApprovedSyndax PharmaceuticalsSmall moleculeInhibitorMenin/Histone-lysine N-methyltransferase MLL inhibitor23

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AMLRevumenibPhase 2Not yet recruitingDana-Farber Cancer InstituteNov 19, 2026
        A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal ImpairmentRevumenibPhase 1Not yet recruitingSyndax PharmaceuticalsNov 6, 2026
        Revumenib in Patients With MyelofibrosisRevumenibPhase 1 / Phase 2Not yet recruitingJohn MascarenhasJul 29, 2026
        Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."RevumenibPhase 2Not yet recruitingTherapeutic Advances in Childhood Leukemia ConsortiumJul 7, 2026
        Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentRevumenibPhase 2Not yet recruitingSWOG Cancer Research NetworkJun 9, 2026
        Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLRevumenibPhase 2Not yet recruitingUNC Lineberger Comprehensive Cancer CenterMay 26, 2026
        Menin-Inhibitor Targeted Maintenance in AMLRevumenibPhase 2Not yet recruitingCenter for International Blood and Marrow Transplant ResearchMay 1, 2026
        A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCTRevumenib—RecruitingThe First Affiliated Hospital of Soochow UniversityApr 30, 2026

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2093861, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.